Jump to content

User:Mr. Ibrahem/Maralixibat

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Maralixibat
Clinical data
Trade namesLivmarli
Other namesLUM001
AHFS/Drugs.comMonograph
License data
Routes of
administration		By mouth
Drug classIleal bile acid transporter (IBAT) inhibitor
Legal status
Legal status
Identifiers
  • 1-[4-({4-[(4R,5R)-3,3-Dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydro-1-benzothiepin-5-yl]phenoxy}methyl)benzyl]-4-aza-1-azoniabicyclo[2.2.2]octane
Chemical and physical data
FormulaC40H56ClN3O4S
Molar mass710.42 g·mol−1
3D model (JSmol)
  • CCCCC1(CCCC)CS(=O)(=O)C2=CC=C(C=C2[C@H]([C@H]1O)C1=CC=C(OCC2=CC=C(C[N+]34CCN(CC3)CC4)C=C2)C=C1)N(C)C
  • InChI=1S/C40H56N3O4S/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H3/q+1/t38-,39-/m1/s1
  • Key:STPKWKPURVSAJF-LJEWAXOPSA-N

Maralixibat, sold under the brand name Livmarli, is a medication used to treat itchiness due to high bile salts in people with Alagille syndrome.[1] It is used in people over the age of 2 month to 1 year.[2][3] It is taken by mouth.[4]

Commons side effects include diarrhea, abdominal pain, low fat soluble vitamins, liver problems, gastrointestinal bleeding, and bone fractures.[1] It is believed to be safe in pregnancy.[3] It is an ileal bile acid transporter (IBAT) inhibitor.[1]

Maralixibat was approved for medical use in the United States in 2021.[1][5] In Europe it is available as an orphan drug.[4] In the United States 30 ml of 9.5 mg/mL solution costs about 54,000 USD as of 2022.[6]

References[edit]

  1. ^ a b c d e f g h "Livmarli- maralixibat chloride solution". DailyMed. Archived from the original on 1 November 2021. Retrieved 31 October 2021.
  2. ^ "Livmarli". Archived from the original on 25 October 2022. Retrieved 26 October 2022.
  3. ^ a b "Maralixibat Monograph for Professionals". Drugs.com. Retrieved 26 October 2022.
  4. ^ a b "Maralixibat". SPS - Specialist Pharmacy Service. 18 July 2019. Archived from the original on 25 September 2021. Retrieved 26 October 2022.
  5. ^ "Maralixibat: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 30 September 2021. Retrieved 29 September 2021.
  6. ^ "Livmarli Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 26 October 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Maralixibat&oldid=1232137648"